Matthew Horn
Pulmonary Disease · Chula Vista, CANPI 1912015637
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,650 of the $90,486 with a category attached, or 89.1%. Johnson & Johnson accounts for 98.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $23,671 and has fallen 98.3% since, to $408 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $619.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$89K
- Boehringer Ingelheim$405
- La Jolla Pharmaceutical Company$314
- Penumbra, Inc.$140
- AbbVie$125
- AstraZeneca$125
- plus $239 from 4 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$80,65089%
- Travel & lodging$4,8525%
- Food & beverage$4,6845%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 129 | $89,139 |
| Boehringer Ingelheim | 6 | $405 |
| La Jolla Pharmaceutical Company | 4 | $314 |
| Penumbra, Inc. | 1 | $140 |
| AbbVie | 1 | $125 |
| AstraZeneca | 1 | $125 |
| Intuitive Surgical | 1 | $106 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $97 |
| GSK | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$87,362
- GIAPREZA$234
- Indigo System$140
- AVYCAZ$125
- BREZTRI$125
- Da Vinci Surgical System$106
How this compares
$90,486 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 13 | $181 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Chula Vista
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.